Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down – Here’s What Happened

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) gapped down prior to trading on Wednesday . The stock had previously closed at $39.75, but opened at $32.72. Supernus Pharmaceuticals shares last traded at $34.98, with a volume of 255,949 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald downgraded Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $57.00 to $36.00 in a research report on Wednesday.

Supernus Pharmaceuticals Stock Performance

The company has a 50-day simple moving average of $37.55 and a 200-day simple moving average of $35.27. The stock has a market cap of $1.83 billion, a P/E ratio of 30.89 and a beta of 0.90.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now owns 10,149 shares in the company, valued at $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in SUPN. Pacer Advisors Inc. raised its position in shares of Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after acquiring an additional 403,028 shares during the last quarter. Woodline Partners LP grew its stake in shares of Supernus Pharmaceuticals by 124.8% during the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company’s stock worth $15,326,000 after purchasing an additional 235,257 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Supernus Pharmaceuticals by 248.0% during the fourth quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company’s stock worth $10,581,000 after purchasing an additional 208,552 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth $6,847,000. Finally, Great Lakes Advisors LLC acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth $6,131,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.